Are you or someone you know struggling with memory loss?
The Apollo E4 Alzheimer’s Disease Research Study
We’re continuing with our mission to help find a cure for Alzheimer’s disease and have now launched a new Alzheimer’s disease research study – Apollo E4.
What is the Apollo E4 study?
The aim of the Apollo E4 study is to test a new investigational drug to see if it helps slow the progression of Alzheimer’s disease.
Currently, there are no approved drugs or therapies that slow or halt the progression of Alzheimer’s entirely, this research study is looking to add valuable data and insight to help change this.
What is the investigational tablet?
The investigational tablet taken as part of this study has been specifically designed to slow the progression of Alzheimer’s disease based on data collected from previous research studies.
The oral tablet is required to be taken twice a day with food over the course of 18 months.
This method of medication was chosen as it has proven to be a well-tolerated treatment in previously studies, and is one of the most convenient options for Alzheimer’s patients.
If you meet all qualifying criteria and are accepted onto this research study, you will receive access to this groundbreaking investigational oral tablet that is not currently available to the general public.
For more reasons on why you should participate in clinical research studies, click here.
Who can participate?
You may qualify to participate in this groundbreaking research study if you fit the following criteria:
- Are between the ages of 50 and 85 years old?
- Are worried about your memory or have a diagnosis of early Alzheimer’s disease?
- Are happy to be tested for the APOE4 gene?
- Have a study partner, either a close relative or friend, who will participate in one study visit per year
If you fit the above criteria, please fill out our quick 3-min pre-screening survey here.
Now that our doors are back open as usual, we look forward to welcoming participants in person at our new state-of-the-art facility in Excel House, Eurocentral.
If you have any questions about participating in this study, or any of our other studies (Evoke Study, Ahead Study, Invoke AL002-2 Study), please don’t hesitate to get in touch on 0141 948 0206 or email email@example.com.
Posted 5th November 2021